AU2005212355B2 - Controlled release formulations - Google Patents

Controlled release formulations Download PDF

Info

Publication number
AU2005212355B2
AU2005212355B2 AU2005212355A AU2005212355A AU2005212355B2 AU 2005212355 B2 AU2005212355 B2 AU 2005212355B2 AU 2005212355 A AU2005212355 A AU 2005212355A AU 2005212355 A AU2005212355 A AU 2005212355A AU 2005212355 B2 AU2005212355 B2 AU 2005212355B2
Authority
AU
Australia
Prior art keywords
morphine
composition according
composition
administration
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005212355A
Other languages
English (en)
Other versions
AU2005212355A1 (en
Inventor
Fred Mermelstein
Michael Moshman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovative Drug Delivery Systems Inc
Original Assignee
Innovative Drug Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Drug Delivery Systems Inc filed Critical Innovative Drug Delivery Systems Inc
Publication of AU2005212355A1 publication Critical patent/AU2005212355A1/en
Application granted granted Critical
Publication of AU2005212355B2 publication Critical patent/AU2005212355B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005212355A 2004-02-10 2005-02-09 Controlled release formulations Ceased AU2005212355B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/776,333 2004-02-10
US10/776,333 US20050175679A1 (en) 2004-02-10 2004-02-10 Controlled release formulations
PCT/US2005/004163 WO2005077346A1 (en) 2004-02-10 2005-02-09 Controlled release formulations

Publications (2)

Publication Number Publication Date
AU2005212355A1 AU2005212355A1 (en) 2005-08-25
AU2005212355B2 true AU2005212355B2 (en) 2010-06-17

Family

ID=34827359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005212355A Ceased AU2005212355B2 (en) 2004-02-10 2005-02-09 Controlled release formulations

Country Status (10)

Country Link
US (2) US20050175679A1 (https=)
EP (1) EP1720532A1 (https=)
JP (1) JP2007522223A (https=)
KR (1) KR20060135769A (https=)
AU (1) AU2005212355B2 (https=)
BR (1) BRPI0506630A (https=)
CA (1) CA2555882A1 (https=)
IL (1) IL177328A0 (https=)
MX (1) MXPA06009094A (https=)
WO (1) WO2005077346A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083984A1 (en) 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
KR100766820B1 (ko) 2006-01-23 2007-10-17 광주과학기술원 단백질 또는 펩타이드의 경점막 운반 시스템
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
JP5258315B2 (ja) * 2007-05-25 2013-08-07 ロート製薬株式会社 フルニソリド含有粘膜適用組成物
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
BR112014004418A8 (pt) * 2011-08-25 2018-01-23 Evoke Pharma Inc método de tratamento de sintomas associados à gastroparesia feminina
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
JP7217071B2 (ja) * 2019-09-30 2023-02-02 エルジー・ケム・リミテッド 高吸水性樹脂およびその製造方法
EP4230206A1 (en) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5629011A (en) * 1992-02-05 1997-05-13 Danbiosyst Uk Limited Composition for nasal administration
US5955502A (en) * 1994-03-30 1999-09-21 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US6387917B1 (en) * 1999-10-20 2002-05-14 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Salts of opioid analgesics, particularly morphine, and methods of using same
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6465626B1 (en) * 1997-01-14 2002-10-15 West Pharmaceutical Services Drug Delivery And Clincal Research Centre, Limited Pharmaceutical compositions of chitosan with type-A gelatin
EP1243256B1 (en) * 2001-03-19 2008-08-13 Grisotech S.A. Vaccines absorbable by the transmucosal way

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5508282C1 (en) * 1993-05-17 2001-01-23 Tulin Silver Jeffrey Composition and method for treating acute or chronic rhinosinusitis
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9605867D0 (en) * 1996-03-20 1996-05-22 Svedman Paul Transdermal device
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
HRP20010926A2 (en) * 1999-06-16 2003-04-30 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5629011A (en) * 1992-02-05 1997-05-13 Danbiosyst Uk Limited Composition for nasal administration
US5955502A (en) * 1994-03-30 1999-09-21 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US6465626B1 (en) * 1997-01-14 2002-10-15 West Pharmaceutical Services Drug Delivery And Clincal Research Centre, Limited Pharmaceutical compositions of chitosan with type-A gelatin
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6387917B1 (en) * 1999-10-20 2002-05-14 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Salts of opioid analgesics, particularly morphine, and methods of using same
EP1243256B1 (en) * 2001-03-19 2008-08-13 Grisotech S.A. Vaccines absorbable by the transmucosal way

Also Published As

Publication number Publication date
MXPA06009094A (es) 2007-02-02
KR20060135769A (ko) 2006-12-29
JP2007522223A (ja) 2007-08-09
IL177328A0 (en) 2006-12-10
CA2555882A1 (en) 2005-08-25
US20050175679A1 (en) 2005-08-11
EP1720532A1 (en) 2006-11-15
AU2005212355A1 (en) 2005-08-25
US20080221144A1 (en) 2008-09-11
BRPI0506630A (pt) 2007-05-08
WO2005077346A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
US9814705B2 (en) Intranasal spray device containing pharmaceutical composition
JP5683719B2 (ja) ベポタスチン組成物
US20080221144A1 (en) Controlled Release Formulations
EP3678649B1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
GB2596592A (en) Pharmaceutical formulation
NZ542218A (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid
AU2020410965B2 (en) Liquid composition comprising ibuprofen and phenylephrine
EP4279062A1 (en) Liquid composition and its use, treatment method and kit
HK40077494B (en) Liquid composition comprising ibuprofen and phenylephrine
HK40077494A (en) Liquid composition comprising ibuprofen and phenylephrine
EA037259B1 (ru) Применение фармацевтической композиции с фиксированной дозой, содержащей мометазон и азеластин, для лечения аллергического ринита и способ лечения аллергического ринита
EA052369B1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания
HK1168539A (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired